Search

Displaying results 4491 - 4500 of 10000 in total
  1. Drug

    Ranpirnase

    go.drugbank.com/drugs/DB04950
    Investigational

    It is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.

  2. Drug

    Nomifensine

    go.drugbank.com/drugs/DB04821
    ApprovedWithdrawn

    Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets. … FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)).

  3. Drug

    Quinacrine

    go.drugbank.com/drugs/DB01103
    Investigational

    It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.

  4. Drug

    Bromopride

    go.drugbank.com/drugs/DB09018
    Investigational

    Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.

  5. Drug

    Eprinomectin

    go.drugbank.com/drugs/DB11405
    ExperimentalVet approved

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Imipramine oxide

    go.drugbank.com/drugs/DB13782
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Lofepramine

    go.drugbank.com/drugs/DB13411
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    As of February 2007 the development of AZD3409 had been discontinued. … AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004.

  9. Drug

    Nebicapone

    go.drugbank.com/drugs/DB14849
    Investigational

    of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg). … Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose

  10. Drug

    Oxypurinol

    go.drugbank.com/drugs/DB05262
    Investigational

    Oxypurinol, an inhibitor of xanthine oxidase, is a metabolite of allopurinol.